Quantitative assessment of the influence of cytochrome P450 2C19 gene polymorphisms and digestive tract cancer risk

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 3083-3091

  Yao, Le ^a   Wang, Hong Cheng ^b   Liu, Jia Zhe ^b   Xiong, Zhao Ming ^a  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

CYP2C19; Digestive tract cancer; Meta analysis; Polymorphism

Indexed keywords

EID: 84885430208     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0875-z     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423-36.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
4. Boffetta P, Couto E, Wichmann J, Ferrari P, Trichopoulos D, Bueno-de-Mesquita HB, et al. Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2010;102:529-37.
5. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429-38.
6. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344-53.
7. Koizumi Y, Tsubono Y, Nakaya N, Kuriyama S, Shibuya D, Matsuoka H, et al. Cigarette smoking and the risk of gastric cancer: a pooled analysis of two prospective studies in Japan. Int J Cancer. 2004;112:1049-55.
8. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol. 2010;52:252-7.
9. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25:193-200.
10. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-50.
11. Tribut O, Lessard Y, Reymann JM, et al. Pharmacogenomics. Med Sci Monit. 2002;8:RA152-63.
12. Kappers WA, Edwards RJ, Murray S, Boobis AR. Diazinon is activated by CYP2C19 in human liver. Toxicol Appl Pharmacol. 2001;177:68-76.
13. Fujita K, Kamataki T. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ Mol Mutagen. 2001;38:339-46.
14. Yamazaki Y, Fujita K, Nakayama K, Suzuki A, Nakamura K, Yamazaki H, et al. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. Mutat Res. 2004;562:151-62.
15. Fujita K, Kamataki T. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase. Mutat Res. 2001;483:35-41.
16. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab. 2002;3:289-309.
17. He N, Yan FX, Huang SL, Wang W, Xiao ZS, Liu ZQ, et al. CYP2C19 genotype and s-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. Eur J Pharmacol. 2002;58:15-8.
18. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
22. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251-3.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
24. Egger M, Davey Smith G, Schneider M. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
25. Shi Y, Luo GJ, Zhang L, Shi J, Zhang DQ, Chen JM, et al. Interaction between alcohol consumption and CYP 2C19 gene polymorphism in relation to oesophageal squamous cell carcinoma. PLoS One. 2012;7:e43412.
26. Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schönfels W, et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer. 2011;18:265-76.
27. Isomura Y, Yamaji Y, Ohta M, Seto M, Asaoka Y, Tanaka Y, et al. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol. 2010;45:1045-52.
28. Chang FH, Zhang ZX, Bai TY, Wang MJ, Fan L, Ma J. The study on the polymorphisms of CYP2C19 genes associated with susceptibility to liver cancer. Zhongguo Yao Li Tong Xun. 2010;27:22-3.
29. Zhang WL, Sheyhidin I, Wu MB, Zhang Z, Li DS, Liu Z. Study on relations between genetic polymorphisms in CYP2C19, GSTT1 and risk of Kazakh's esophageal cancer in Xinjiang. Shiyong Zhongliu Za Zhi. 2009;24:232-6.
30. Jiang W, Shao JG, Lu JR. Relationship between cytochrome P450 2C19 gene polymorphism and primary hepatocellular carcinoma. Wei Chang Bing Xue. 2008;13:39-41.
31. Yang ZF, Bi LF, Su XL. Cytochrome P450 and tumor susceptibility. Zhongliu Yan Jiu Yu Lin Chuang. 2008;20:65-7.
32. Tamer L, Ercan B, Ercan S, Ateş N, Ateş C, Ocal K, et al. CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma. Int J Gastrointest Cancer. 2006;37:1-5.
33. Zhou YL, Chen HF, Shi XS, Zhou ZJ, Li GQ, Pan PC, et al. A case-control study on the polymorphisms of NQO1 and susceptibility of esophageal cancer. Zhongguo Zhong Liu. 2006;15:659-63.
34. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics. 2005;15:535-46.
35. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Sugimura H, et al. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;22:1033-40.
36. Mochizuki J, Murakami S, Sanjo A, Takagi I, Akizuki S, Ohnishi A. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2005;20:1191-7.
37. Shi WX, Chen SQ. Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J Gastroenterol. 2004;10:1961-3.
38. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis. 2002;23:1839-49.
39. Drögemöller BI, Wright GE, Niehaus DJ, Koen L, Malan S, Da Silva DM, et al. Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics. 2010;11:1095-103.
40. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121:512-8.
41. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-22.
42. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4:285-99.
43. Han XM, Zhou HH. Polymorphism of CYP450 and cancer susceptibility. Acta Pharmacol Sin. 2000;21:673-9.
44. Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol. 2000;49:485-8.
45. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997;40:297-301.
46. Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis. 2011;32:1107-21.